Contact
searchSearch
HMP Global

Diffuse Large B-Cell Lymphoma Topic Center

Industry Insights
News

news


News
From Indolent to Aggressive: Understanding Lymphoma Transformation
04/09/2024
Hannah Musick
“Histologic transformation of indolent lymphoma to aggressive lymphoma, most commonly DLBCL, represents a well-recognized event,” said researchers. “While work in the past decade has shed light on many of the genetic and biological changes of...
“Histologic transformation of indolent lymphoma to aggressive lymphoma, most commonly DLBCL, represents a well-recognized event,” said researchers. “While work in the past decade has shed light on many of the genetic and biological changes of...
“Histologic transformation of...
04/09/2024
First Report Managed Care
News
Early, Late DLBCL Relapse Linked With Distinct Evolutionary Dynamics
08/17/2023
Jolynn Tumolo
“These observations have implications for clinical trial design and patient management, where early and late relapse patient populations should be considered separately and support additional molecular characterization of tumors at relapse to...
“These observations have implications for clinical trial design and patient management, where early and late relapse patient populations should be considered separately and support additional molecular characterization of tumors at relapse to...
“These observations have...
08/17/2023
First Report Managed Care
News
No Access to CAR-T Therapy Raises Mortality for Louisiana Medicaid Patients With DLBCL 
08/02/2023
Jolynn Tumolo
“The state of Louisiana currently does not have any institution which offers CAR-T therapy. Our Medicaid population is further disadvantaged by the fact that their insurance does not cover out-of-state services,” researchers said.
“The state of Louisiana currently does not have any institution which offers CAR-T therapy. Our Medicaid population is further disadvantaged by the fact that their insurance does not cover out-of-state services,” researchers said.
“The state of Louisiana...
08/02/2023
First Report Managed Care
News
Zanubrutinib Plus R-CHOP Effective for Non-GCB DLBCL With Extranodal Involvement
08/02/2023
Jolynn Tumolo
Researchers studied the efficacy and safety of a combination regimen that included zanubrutinib among treatment-naïve patients with non–germinal center B cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL) with multiple extranodal...
Researchers studied the efficacy and safety of a combination regimen that included zanubrutinib among treatment-naïve patients with non–germinal center B cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL) with multiple extranodal...
Researchers studied the efficacy...
08/02/2023
First Report Managed Care
News
Study Finds Low Rate of CAR T-cell Therapy in Older Adults With DLBCL
07/27/2023
Jolynn Tumolo
"CAR T-cell therapy was associated with favorable effectiveness, but the CAR T-cell therapy use in older patients was very low," particularly among patients aged at least 75 years, according to researchers.
"CAR T-cell therapy was associated with favorable effectiveness, but the CAR T-cell therapy use in older patients was very low," particularly among patients aged at least 75 years, according to researchers.
"CAR T-cell therapy was...
07/27/2023
First Report Managed Care
News
CNS Prophylaxis Shows Limited Effectiveness in Preventing CNS Relapse in DLBCL
07/21/2023
Jolynn Tumolo
In addition to effectiveness, researchers also evaluated the financial toxicity and side effects associated with CNS prophylaxis for patients with diffuse large B-cell lymphoma. 
In addition to effectiveness, researchers also evaluated the financial toxicity and side effects associated with CNS prophylaxis for patients with diffuse large B-cell lymphoma. 
In addition to effectiveness,...
07/21/2023
First Report Managed Care
News
Prognosis Worse for Patients With DLBCL and Mental Health Disorders
07/20/2023
Julie Gould
Among patients with diffuse large B-cell lymphoma, pre-existing depression and anxiety were both associated with worse prognoses, according to recent findings.
Among patients with diffuse large B-cell lymphoma, pre-existing depression and anxiety were both associated with worse prognoses, according to recent findings.
Among patients with diffuse...
07/20/2023
First Report Managed Care
News
Epcoritamab Shows Durable Response in Relapsed/Refractory Large B-Cell Lymphoma
07/14/2023
Jolynn Tumolo
“The observed high response rates with durability in patients with refractory large B-cell lymphoma treated with epcoritamab, including postchimeric antigen receptor-T therapy, represent further evidence of the value of bispecific antibodies...
“The observed high response rates with durability in patients with refractory large B-cell lymphoma treated with epcoritamab, including postchimeric antigen receptor-T therapy, represent further evidence of the value of bispecific antibodies...
“The observed high response...
07/14/2023
First Report Managed Care
News
Biosimilar Rituximab Compared to Originator Rituximab for Treatment of Patients With DLBCL
05/12/2023
Jordan Kadish
According to findings from a phase 3 trial, biosimilar rituximab had comparable efficacy and safety to originator rituximab among patients with diffuse large B-cell lymphoma.
According to findings from a phase 3 trial, biosimilar rituximab had comparable efficacy and safety to originator rituximab among patients with diffuse large B-cell lymphoma.
According to findings from a...
05/12/2023
Oncology
News
Anti-CD19 Monoclonal Antibodies for Treating Patients With R/R DLBCL
05/20/2022
Maria Asimopoulos
Researchers reviewed loncastuximab tesirine and tafasitamab for treating patients with relapsed or refractory diffuse large B-cell lymphoma.
Researchers reviewed loncastuximab tesirine and tafasitamab for treating patients with relapsed or refractory diffuse large B-cell lymphoma.
Researchers reviewed...
05/20/2022
First Report Managed Care

Behind the Bill

Behind the Bill
The Medicare Paradox: How Tariffs Could Undermine IRA Drug Pricing Reforms
04/23/2025
Katie Hayes, MJ
The Trump administration's recent announcement of national security investigations into pharmaceutical imports has set up a potential collision course with one of the most significant health care reforms in recent years. While the White...
The Trump administration's recent announcement of national security investigations into pharmaceutical imports has set up a potential collision course with one of the most significant health care reforms in recent years. While the White...
The Trump administration's...
04/23/2025
First Report Managed Care
Behind the Bill
The Bitter Pill, Now in Motion: Pharma Tariffs Move from Rhetoric to Reality
04/16/2025
Katie Hayes, MJ
Last week, I flagged the growing risk that tariffs could upend affordability in the generics market. This week, the Trump administration made it official: it’s launching national security investigations under Section 232 of the Trade...
Last week, I flagged the growing risk that tariffs could upend affordability in the generics market. This week, the Trump administration made it official: it’s launching national security investigations under Section 232 of the Trade...
Last week, I flagged the growing...
04/16/2025
First Report Managed Care
Behind the Bill
The Bitter Pill: How Tariffs Could Make Generics Less Affordable
04/09/2025
Katie Hayes, MJ
As President Donald Trump’s administration introduces a series of tariffs aimed at rebalancing trade and boosting US manufacturing, one sector in particular is watching closely: pharmaceuticals. While drugs themselves may not be directly...
As President Donald Trump’s administration introduces a series of tariffs aimed at rebalancing trade and boosting US manufacturing, one sector in particular is watching closely: pharmaceuticals. While drugs themselves may not be directly...
As President Donald Trump’s...
04/09/2025
First Report Managed Care
Behind the Bill
SCOTUS Takes on the Nondelegation Doctrine: Surprising Reactions and What They Mean for Agency Power
04/02/2025
Katie Hayes, MJ
The Supreme Court recently heard arguments in Federal Communication Commission (FCC) v Consumers’ Research, a case that I covered in February and one that could dramatically reshape federal agency authority through the nondelegation...
The Supreme Court recently heard arguments in Federal Communication Commission (FCC) v Consumers’ Research, a case that I covered in February and one that could dramatically reshape federal agency authority through the nondelegation...
The Supreme Court recently heard...
04/02/2025
First Report Managed Care
Behind the Bill
Dr Oz’s Prescription for Making Medicaid “Viable at Every Level”
03/26/2025
Katie Hayes, MJ
On Tuesday, March 25, 2025, the Senate Finance Committee voted to advance Dr Mehmet Oz in his confirmation as the next head of the Centers for Medicare and Medicaid Services (CMS).1 The full Senate vote is expected “soon” (whatever that...
On Tuesday, March 25, 2025, the Senate Finance Committee voted to advance Dr Mehmet Oz in his confirmation as the next head of the Centers for Medicare and Medicaid Services (CMS).1 The full Senate vote is expected “soon” (whatever that...
On Tuesday, March 25, 2025, the...
03/26/2025
First Report Managed Care
Behind the Bill
The $880 Billion Question Continues: Dr Oz's Confirmation and the Future of Medicaid
03/19/2025
Katie Hayes, MJ
Last week, I explored the $880 billion question facing Congress—whether lawmakers could achieve their budget goals without cutting Medicaid. This week, that question took center stage as Dr Mehmet Oz, President Trump's nominee to lead the...
Last week, I explored the $880 billion question facing Congress—whether lawmakers could achieve their budget goals without cutting Medicaid. This week, that question took center stage as Dr Mehmet Oz, President Trump's nominee to lead the...
Last week, I explored the $880...
03/19/2025
First Report Managed Care
Behind the Bill
The $880 Billion Question: Can Congress Cut Spending Without Touching Medicaid?
03/12/2025
Katie Hayes, MJ
I’d like to step away from administrative law for a moment to provide a quick update on Medicaid. With news coming from all sides, what does the future of Medicaid actually look like? The House of Representatives narrowly passed a budget...
I’d like to step away from administrative law for a moment to provide a quick update on Medicaid. With news coming from all sides, what does the future of Medicaid actually look like? The House of Representatives narrowly passed a budget...
I’d like to step away from...
03/12/2025
First Report Managed Care
Behind the Bill
RFK Jr’s Public Comment Ban: The Silent Shift in Health Care Rulemaking
03/05/2025
Katie Hayes, MJ
The erosion of administrative law continues, and with it, the dismantling of decades-long precedent. In June, the Supreme Court overturned a 40-year-old doctrine that allowed federal agencies to interpret their own ambiguous statutes. Later...
The erosion of administrative law continues, and with it, the dismantling of decades-long precedent. In June, the Supreme Court overturned a 40-year-old doctrine that allowed federal agencies to interpret their own ambiguous statutes. Later...
The erosion of administrative...
03/05/2025
First Report Managed Care
Behind the Bill
Prevention Over Pills? The First 2 Weeks of Health Care’s New Direction
02/26/2025
Katie Hayes, MJ
The dust has barely settled from Robert F Kennedy Jr’s confirmation as Secretary of Health and Human Services (HHS), but the changes are already coming fast and furious—a key theme of the Trump Administration’s actions within the last several...
The dust has barely settled from Robert F Kennedy Jr’s confirmation as Secretary of Health and Human Services (HHS), but the changes are already coming fast and furious—a key theme of the Trump Administration’s actions within the last several...
The dust has barely settled from...
02/26/2025
First Report Managed Care
Behind the Bill
The Nondelegation Doctrine: The Next Constitutional Showdown (Part 2)
02/19/2025
Katie Hayes, MJ
Last week, I explored the potential revival of the nondelegation doctrine through Federal Communication Commission v Consumers’ Research. Today, I want to examine what this could mean for health care regulation by considering the parallels...
Last week, I explored the potential revival of the nondelegation doctrine through Federal Communication Commission v Consumers’ Research. Today, I want to examine what this could mean for health care regulation by considering the parallels...
Last week, I explored the...
02/19/2025
First Report Managed Care

Subscribe and Stay Ahead With Daily Industry Insights

First Report Managed Care Newsletter

Trending Articles

News
Value Assessment Tools: What Is Valuable to Payers?
05/26/2023
Julie Gould
“US health care payers perceive select value assessment tools to be useful for informing health care decisions,” explained the authors of a recent study.
“US health care payers perceive select value assessment tools to be useful for informing health care decisions,” explained the authors of a recent study.
“US health care payers perceive...
05/26/2023
First Report Managed Care
News
Monoclonal Antibody Improves Disease Control in Patients With Severe Asthma and CRSwNP
06/20/2023
Julie Gould
“Our results consolidate the strategic position of dupilumab in its role as an excellent therapeutic option currently available within the context of modern biological treatments of severe asthma and CRSwNP, frequently driven by type 2 airway...
“Our results consolidate the strategic position of dupilumab in its role as an excellent therapeutic option currently available within the context of modern biological treatments of severe asthma and CRSwNP, frequently driven by type 2 airway...
“Our results consolidate the...
06/20/2023
First Report Managed Care
News
Psychometric Evaluation Supports Use of RiiQ Symptoms Scales in RSV Trials
07/19/2023
Jolynn Tumolo
In this study, the psychometric properties of the Respiratory Infection Intensity and Impact Questionnaire (RiiQ) were evaluated to test reliability and validity for use in clinical studies.
In this study, the psychometric properties of the Respiratory Infection Intensity and Impact Questionnaire (RiiQ) were evaluated to test reliability and validity for use in clinical studies.
In this study, the psychometric...
07/19/2023
Pharmacy Learning Network
News
Gene Therapy for Hemophilia: Considering Therapeutic Value, Patient Selection
08/09/2023
Hannah Musick
Authors of a recent review discussed the value of emerging gene therapies for patients with hemophilia, emphasizing that one of the biggest challenges remains the appropriate selection of patients.
Authors of a recent review discussed the value of emerging gene therapies for patients with hemophilia, emphasizing that one of the biggest challenges remains the appropriate selection of patients.
Authors of a recent review...
08/09/2023
First Report Managed Care
News
Study Finds No Significant Link between eGFR and DME in Latino Patients
09/06/2023
Jolynn Tumolo
There was no association between glomerular filtration rate and diabetic macular edema (DME) in a study of Latino patients with type 2 diabetes and DME.
There was no association between glomerular filtration rate and diabetic macular edema (DME) in a study of Latino patients with type 2 diabetes and DME.
There was no association between...
09/06/2023
First Report Managed Care

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use